QuartrQuartr

PharmaEssentia: H1 2025 saw revenue and net income surge, with strong cash reserves and key legal disputes resolved

1分未満で読めます

Revenue and net income more than doubled year-over-year for H1 2025, driven by strong product sales and global expansion. Arbitration with AOP largely resolved, with most claims dismissed and some liabilities recognized. Robust cash position supports ongoing R&D and manufacturing growth.

Original document: PharmaEssentia Corp. [6446] Interim report — Aug. 28 2025

免責事項